- Home
- KC vs KYMR Comparison
KC vs KYMR Comparison
Compare KC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KC
- KYMR
- Stock Information
- Founded
- KC 2012
- KYMR 2015
- Country
- KC China
- KYMR United States
- Employees
- KC N/A
- KYMR N/A
- Industry
- KC Computer Software: Prepackaged Software
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- KC Technology
- KYMR Health Care
- Exchange
- KC Nasdaq
- KYMR Nasdaq
- Market Cap
- KC 4.3B
- KYMR 4.3B
- IPO Year
- KC 2020
- KYMR 2020
- Fundamental
- Price
- KC $12.60
- KYMR $61.84
- Analyst Decision
- KC Strong Buy
- KYMR Strong Buy
- Analyst Count
- KC 4
- KYMR 18
- Target Price
- KC $13.55
- KYMR $65.56
- AVG Volume (30 Days)
- KC 1.6M
- KYMR 611.9K
- Earning Date
- KC 11-18-2025
- KYMR 11-04-2025
- Dividend Yield
- KC N/A
- KYMR N/A
- EPS Growth
- KC N/A
- KYMR N/A
- EPS
- KC N/A
- KYMR N/A
- Revenue
- KC $1,177,715,737.00
- KYMR $44,711,000.00
- Revenue This Year
- KC $25.35
- KYMR $60.88
- Revenue Next Year
- KC $16.46
- KYMR N/A
- P/E Ratio
- KC N/A
- KYMR N/A
- Revenue Growth
- KC 20.27
- KYMR N/A
- 52 Week Low
- KC $2.70
- KYMR $19.45
- 52 Week High
- KC $22.26
- KYMR $63.96
- Technical
- Relative Strength Index (RSI)
- KC 41.12
- KYMR 61.40
- Support Level
- KC $12.53
- KYMR $58.76
- Resistance Level
- KC $13.93
- KYMR $62.03
- Average True Range (ATR)
- KC 0.43
- KYMR 2.87
- MACD
- KC 0.02
- KYMR -0.15
- Stochastic Oscillator
- KC 30.37
- KYMR 75.63
About KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.